{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013836","form_type":"8-K","ticker":"USAQ","cik":"0000856984","company_name":"QHSLab, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.833454+00:00","generated_at":"2026-05-15T08:18:46.748515+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"QHSLab reports fiscal 2025 net income of $457K, revenue up 26% to $2.69M","bullets":["Revenue $2.69M (+26% YoY); net income $457,417 vs net loss $259,239 in 2024.","Gross margin expanded to 67.3% from 63.7%; gross profit $1.81M vs $1.36M.","Current liabilities reduced to ~$450K from ~$2.4M; cash increased to $636K from $157K.","ISP revenue grew 74% YoY to $1.12M; immunotherapy sales up ~19%.","Recorded ~$1.15M gain on extinguishment of convertible debt; interest expense halved to $237K."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013836","json":"https://secwatch.observer/filing/0001493152-26-013836.json","markdown":"https://secwatch.observer/filing/0001493152-26-013836.md","text":"https://secwatch.observer/filing/0001493152-26-013836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/856984/000149315226013836/0001493152-26-013836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/856984/000149315226013836/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:18:46.748515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}